Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario Forum
Cheema P, Wheatley-Price P, Cecchini M, Ellis P, Louie A, Moore S, Sheffield B, Spicer J, Villeneuve P, Leighl N. Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario Forum. Current Oncology 2024, 31: 6979-6999. DOI: 10.3390/curroncol31110514.Peer-Reviewed Original ResearchNon-small cell lung cancerEarly-stage non-small cell lung cancerImmune checkpoint inhibitorsCell lung cancerLung cancerManagement of early-stage non-small cell lung cancerPre-meeting surveyTreatment approachesReview practice patternsAdjuvant settingCheckpoint inhibitorsRadiation therapyOntario cancer centersTargeted therapySurgical considerationsTreatment algorithmReview recent dataClinical dataBiomarker testingCancer CenterTherapeutic strategiesPractice patternsCancerTherapyPatientsGrowth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy
Di Pastena F, Pond G, Tsakiridis E, Gouveia A, Ahmadi E, Biziotis O, Ali A, Swaminath A, Okawara G, Ellis P, Abdulkarim B, Ahmed N, Robinson A, Roa W, Valdes M, Kavsak P, Wierzbicki M, Wright J, Steinberg G, Tsakiridis T. Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy. Radiation Oncology 2024, 19: 155. PMID: 39511611, PMCID: PMC11542377, DOI: 10.1186/s13014-024-02546-y.Peer-Reviewed Original ResearchConceptsLocally advanced non-small cell lung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerOverall survivalDifferentiation factor 15GDF15 levelsLA-NSCLCTumor volumeSurvival outcomesUnresectable locally advanced non-small cell lung cancerLung cancerPhase II randomized clinical trialConcurrent chest radiotherapyIncreased GDF15 levelsUnresectable LA-NSCLCTreated with chemoradiotherapyGross target volumeGrowth differentiation factor 15Platinum-based chemotherapyPlasma GDF15 levelsRandomized to treatmentLevels of GDF15Patient blood plasmaRandomized clinical trialsImplementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective
Breadner D, Hwang D, Husereau D, Cheema P, Doucette S, Ellis P, Kassam S, Leighl N, Maziak D, Selvarajah S, Sheffield B, Juergens R. Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective. Current Oncology 2024, 31: 6017-6031. PMID: 39451753, PMCID: PMC11505603, DOI: 10.3390/curroncol31100449.Peer-Reviewed Original ResearchNon-small-cell lung cancerAdvanced non-small-cell lung cancerCirculating tumor DNALung cancerMolecular profilingLiquid biopsyImplementation of liquid biopsiesComprehensive molecular profilingNon-small-cellHigh-risk patientsCancer-related deathsMinimally invasive methodTissue biopsy samplesTumor DNAInsufficient tissueMultidisciplinary working groupTherapy selectionTissue biopsiesBiomarker testingBiopsy samplesBiopsyGold standardInvasive methodEligibility criteriaCancer